featured
Maintenance Strategies After First-Line Oxaliplatin Plus Fluoropyrimidine Plus Bevacizumab in Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Maintenance Strategies After First-Line Oxaliplatin Plus Fluoropyrimidine Plus Bevacizumab for Patients With Metastatic Colorectal Cancer (AIO 0207): A Randomised, Non-Inferiority, Open-Label, Phase 3 Trial
Lancet Oncol 2015 Sep 08;[EPub Ahead of Print], S Hegewisch-Becker, U Graeven, CA Lerchenmüller, B Killing, R Depenbusch, CC Steffens, SE Al-Batran, T Lange, G Dietrich, J Stoehlmacher, A Tannapfel, A Reinacher-Schick, J Quidde, T Trarbach, A Hinke, HJ Schmoll, D ArnoldFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.